Online citations, reference lists, and bibliographies.

Malignant Pleural Mesothelioma.

A. Tsao, I. Wistuba, J. Roth, H. Kindler
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a deadly disease that occurs in 2,000 to 3,000 people each year in the United States. Although MPM is an extremely difficult disease to treat, with the median overall survival ranging between 9 and 17 months regardless of stage, there has been significant progress over the last few years that has reshaped the clinical landscape. This article will provide a comprehensive discussion of the latest developments in the treatment of MPM. We will provide an update of the major clinical trials that impact mesothelioma treatment in the resectable and unresectable settings, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. In addition, there are controversial issues, such as the role of extrapleural pneumonectomy, adjuvant radiotherapy, and use of intensity-modulated radiotherapy versus hemithoracic therapy that will also be addressed in this manuscript.
This paper references
10.1053/j.semtcvs.2009.06.011
Current trends in radiologic management of malignant pleural mesothelioma.
Ritu R Gill (2009)
10.1016/J.LUNGCAN.2006.11.005
A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience.
M. Metintas (2007)
10.2214/AJR.09.3519
Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
R. Gill (2010)
10.1200/JCO.2000.18.11.2293
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
K. Fizazi (2000)
10.1378/chest.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
Phase II trial of mitomycin in malignant mesothelioma.
D. Bajorin (1987)
10.1016/S0169-5002(07)70279-9
203 Pemetrexed in combination with carboplatin for the treatment of patients with malignant mesothelioma
Maximilian Papi (2006)
10.1158/1078-0432.CCR-05-0405
Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy
D. Sterman (2005)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
10.1016/j.ejcts.2009.12.039
Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?
Apostolos Nakas (2010)
10.1016/S0169-5002(07)70273-8
197 Pemetrexed (MTA) and carboplatin (CBDCA) in advanced pleural mesothelioma (MPM): Evaluation of the activity and toxicity in a series of 178 chemonaive patients
C. Bruno (2006)
10.1200/JCO.1993.11.8.1559
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
A. Chahinian (1993)
10.1007/BF00175403
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
B. Zidar (2004)
10.1158/0008-5472.CAN-05-4642
Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey.
A. Dogan (2006)
10.1007/s00280-006-0243-4
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
C. Porta (2006)
10.1093/ANNHYG/46.SUPPL_1.160
Malignant Mesothelioma in Australia, 1945–2000
J. Leigh (2002)
10.1097/JTO.0b013e31819f2e0e
Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure
H. Roberts (2009)
10.1016/S1556-0864(15)30351-8
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1016/j.ejcts.2008.03.003
Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
C. Aigner (2008)
10.1016/S0022-5223(96)70342-2
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1016/J.JTCVS.2005.11.044
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
10.1378/CHEST.113.1_SUPPLEMENT.61S
Multimodality management of malignant pleural mesothelioma.
D. Sugarbaker (1998)
10.1200/JCO.2008.26.15_SUPPL.8063
Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)
A. Nowak (2008)
10.1097/01.coc.0000144852.75613.56
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
10.1016/S0169-5002(07)70302-1
226 Activation of 4E-BP1 represses IGF-1 mediated capdependent translation in malignant pleural mesothelioma
B. Jacobson (2006)
10.1053/SONC.2002.30228
The role of imaging in malignant pleural mesothelioma.
E. Marom (2002)
10.1200/JCO.1999.17.10.3009
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
R. Thödtmann (1999)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1200/JCO.2007.14.7611
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
P. Jänne (2008)
10.1016/j.jtcvs.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1016/S0169-5002(07)70286-6
210 A comparison of CALGB and EORTC paradigms in the assessment of ONCONASE for the treatment of unresectable malignant mesothelioma (UMM)
J. V. Pawel (2006)
10.3816/CLC.2003.N.023
Chemotherapy for malignant pleural mesothelioma.
P. Jänne (2003)
10.1016/J.IJROBP.2005.03.041
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.
V. Gupta (2005)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1158/1078-0432.CCR-07-1388
Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts
P. Bertino (2008)
10.1097/JTO.0b013e3181a0d82e
The IASLC Lung Cancer Staging Project: A Proposal for a New International Lymph Node Map in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer
V. Rusch (2009)
10.1016/J.LUNGCAN.2005.03.030
CT, RECIST, and malignant pleural mesothelioma.
A. Nowak (2005)
10.1002/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P
Malignant mesothelioma. The eastern cooperative oncology group (ECOG) experience
H. Lerner (1983)
10.1517/14712598.6.4.391
Ranpirnase – an antitumour ribonuclease: its potential role in malignant mesothelioma
N. Pavlakis (2006)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1002/ajim.20892
Asbestos is still with us: Repeat call for a universal ban.
Collegium Ramazzini (2011)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1378/chest.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1016/j.lungcan.2003.10.011
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
G. Otterson (2004)
10.1007/s004280050388
Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma
J. König (1999)
10.1200/JCO.1996.14.3.1007
Chemotherapy in malignant pleural mesothelioma. A review.
S. T. Ong (1996)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
10.1179/oeh.2007.13.4.398
Incidence and Descriptive Epidemiology of Mesothelioma in the United States, 1999–2002
Theodore C. Larson (2007)
10.1007/S002680020021
Treatment of Malignant Mesothelioma
M. Jaklitsch (2001)
10.1097/JTO.0b013e3181ae25bf
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia
A. Hasani (2009)
10.3816/CLC.2006.N.003
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
L. Krug (2006)
A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas.
J. Testa (1998)
10.1016/j.ijheh.2009.09.001
Cancer mortality in a surveillance cohort of German males formerly exposed to asbestos.
B. Pesch (2010)
10.1038/bjc.1996.465
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
J. Van Meerbeeck (1996)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1016/S0169-5002(07)70293-3
217 IGF pathway activation in mesothelioma
R. Kratzke (2006)
10.1016/S0169-5002(07)70287-8
211 Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma: CALGB 30307
P. Jänne (2006)
10.1016/J.LUNGCAN.2007.09.018
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
S. Kalmadi (2008)
10.1093/oxfordjournals.aje.a009093
Analysis of current trends in United States mesothelioma incidence.
B. Price (1997)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1136/OEM.2007.034769
Mesothelioma mortality in men: trends during 1977–2001 and projections for 2002–2016 in Spain
S. Pitarque (2007)
10.1016/S0140-6736(04)17108-0
Pleural mesothelioma: little evidence, still time to do trials
T. Treasure (2004)
10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1200/JCO.2007.12.5641
Phase II study of vinflunine in malignant pleural mesothelioma.
D. Talbot (2007)
10.1016/J.IJROBP.2007.02.047
Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
A. Allen (2007)
10.4161/epi.1.1.2644
Histone Deacetylase Inhibitors for Cancer Therapy
T. Kim (2006)
10.1002/1097-0142(19860515)57:10<1905::AID-CNCR2820571003>3.0.CO;2-J
Mesothelioma and mineral fibers
J. Wagner (1986)
10.1089/HUM.1998.9.7-1083
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.
D. Sterman (1998)
10.1097/JTO.0b013e31817c73ec
Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
Paul Taylor (2008)
10.1158/1535-7163.MCT-07-0052
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
A. Tsao (2007)
10.1200/JCO.1990.8.1.151
Phase II trial of carboplatin in the management of malignant mesothelioma.
D. Raghavan (1990)
10.1016/J.EJCTS.2007.09.039
The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma.
A. Nakas (2008)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1016/j.jtcvs.2008.12.045
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
Tristan D. Yan (2009)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
10.1016/S1556-0864(15)31509-4
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
10.1016/J.LUNGCAN.2005.03.020
Soluble mesothelin-related protein--a blood test for mesothelioma.
B. Robinson (2005)
10.1038/sj.bjc.6601957
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
S. Bydder (2004)
10.1016/J.HOC.2005.09.008
Antiangiogenic therapies for mesothelioma.
J. Dowell (2005)
10.1016/S0169-5002(07)70280-5
204 Proteasome inhibitors for treatment of malignant mesothelioma
D. Fennel (2006)
10.1016/S0169-5002(07)70281-7
205 Preclinical studies of the proteosome inhibtor bortezomib (velcade) in malignant pleural mesothelioma (MPM)
G. Gordon (2006)
10.1200/JCO.2005.07.050
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1023/A:1026438215309
High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.
N. Vogelzang (1999)
10.1016/j.jtcvs.2008.02.069
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1165/AJRCMB.25.5.4539
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma.
X. Cao (2001)
10.1038/sj.bjc.6600118
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.1038/bjc.1992.200
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
O. Solheim (1992)
10.1038/nm0897-913
The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas
A. Luca (1997)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
10.1200/JCO.2006.06.6290
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
J. Weingart (2007)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1016/J.LUNGCAN.2004.12.002
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
H. Kindler (2005)
10.1016/j.lungcan.2009.08.019
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
Servet Boeluekbas (2011)
10.1016/J.EJCA.2007.08.028
Mesothelin targeted cancer immunotherapy.
R. Hassan (2008)
10.1200/JCO.2007.11.1336
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
P. Jänne (2007)
10.1016/S0169-5002(07)70268-4
192 Pemetrexed second-line treatment in malignant pleural mesothelioma following platinum-based first-line treatment
J. Sørensen (2006)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
10.1038/sj.bjc.6604421
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
J. Sørensen (2008)
10.1093/annonc/mdj912
Malignant pleural mesothelioma.
P. Baas (1998)
10.1016/0169-5002(94)00404-B
Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients.
L. Tammilehto (1995)
10.1016/j.jtcvs.2006.06.044
Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2007)
10.1200/jco.1993.11.6.1172
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
D. Sugarbaker (1993)
10.1158/1078-0432.CCR-07-0883
Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors
Y. Ali (2007)
10.1158/1078-0432.CCR-10-0806
Fine-Needle Aspiration Biopsies for Gene Expression Ratio-Based Diagnostic and Prognostic Tests in Malignant Pleural Mesothelioma
A. De Rienzo (2010)
10.1200/JCO.2005.05.1359
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.
J. Francart (2006)
10.1136/oem.2003.010165
Changing trends in US mesothelioma incidence
H. Weill (2004)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.1016/S0169-5002(07)70275-1
199 Sequential topoisomerase targeting triplet chemotherapy with irinotecan/cisplatin followed by doxorubicin in patients with malignant pleural mesothelioma: A pilot phase II study
T. Nakano (2006)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1016/J.LUNGCAN.2005.04.010
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
10.1002/(SICI)1097-0142(19990601)85:11<2375::AID-CNCR12>3.0.CO;2-E
Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma
T. Nakano (1999)
10.1016/S0169-5002(07)70278-7
202 Combination chemotherapy with methotrexate, irinotecan, and doxorubicin in malignant pleural mesothelioma: A phase II study
K. Kuribayashi (2006)
10.1016/J.LUNGCAN.2004.10.005
Thalidomide in patients with malignant pleural mesothelioma.
P. Baas (2005)
10.1016/S0169-5002(03)00292-7
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1016/S0169-5002(07)70112-5
36 Health effects among World Trade Center responders
S. Levin (2006)
10.1158/1078-0432.CCR-03-0801
Mesothelin: a new target for immunotherapy.
R. Hassan (2004)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1016/j.athoracsur.2008.04.012
Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma.
A. Abdel Rahman (2008)
10.1016/J.THORSURG.2004.06.006
Patterns of failure following surgical resection for malignant pleural mesothelioma.
P. Jänne (2004)
10.1148/RG.241035058
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
Z. Wang (2004)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
10.1053/SONC.2002.30227
The pathogenesis of mesothelioma.
M. Carbone (2002)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.1016/S0169-5002(07)70277-5
201 Treatment with gemcitabine and vinorelbine (GEMVIN) as second-line chemotherapy in pemetrexed-pretreated patients with malignant pleural mesothelioma (MPM)
P. Zucali (2006)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1200/JCO.2005.00.802
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
C. Lu (2005)
10.1136/oem.57.7.488
Future trends in mortality of French men from mesothelioma
A. Banaei (2000)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1016/j.hoc.2005.09.004
Gene therapy for malignant pleural mesothelioma.
D. Sterman (1998)
10.1093/CARCIN/21.5.1023
mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats.
H. Sandhu (2000)
10.1016/S0169-5002(98)90133-7
Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV.
S. Aversa (1999)
10.1089/HUM.1998.9.14-2121
Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma.
K. Molnar-Kimber (1998)
10.1016/S0140-6736(00)04013-7
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey
Iman Roushdy-Hammady (2001)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1007/BF02303746
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
10.1002/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D
Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma.
S. Kumar-Singh (1997)
10.1158/1078-0432.CCR-07-0403
A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
D. Sterman (2007)
10.1200/JCO.2003.05.123
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
K. Fizazi (2003)
10.1023/A:1008236010868
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.
George W. Middleton (1998)
Simian virus 40-like DNA sequences in human pleural mesothelioma.
M. Carbone (1994)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
10.1016/J.CANLET.2005.02.009
Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells.
J. Sonnemann (2006)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
10.1002/cncr.11405
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
10.1097/JTO.0b013e3181dd0ef1
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.3816/CLC.1999.N.006
Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV.
S. Aversa (1999)
10.1002/cncr.24886
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases
W. Richards (2010)
10.1093/JNCI/91.2.169
Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.
Y. C. Xie (1999)
10.3816/CLC.2004.N.008
Integration of multimodality approaches in the management of malignant pleural mesothelioma.
Derlis Martino (2004)
10.1136/oem.60.1.50
Update of predictions of mortality from pleural mesothelioma in the Netherlands
O. Segura (2003)
10.1016/S0169-5002(07)70294-5
218 Effects of insulin-like growth factor binding protein-3 on human malignant pleural mesothelioma cell growth and apoptosis
Farideh Miraki-Moud (2006)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1097/01.JTO.0000283706.79968.0E
P1-091: Preoperative staging procedures using 18F-FDG-Positron Emission Tomography-Computed Tomography fused imaging (PET-CT-Scan) and Mediastinoscopy compared to Surgical-Pathological findings in Malignant Pleural Mesothelioma undergoing Extrapleural Pneumonectomy
J. Sørensen (2007)
10.1510/ICVTS.2007.166322
Radical surgery for malignant pleural mesothelioma: results and prognosis.
M. Okada (2008)
10.1007/s00330-008-0918-9
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
10.1002/cncr.23617
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
10.1118/1.3525836
Computerized segmentation and measurement of malignant pleural mesothelioma.
W. Sensakovic (2011)
10.1016/J.EJSO.2004.08.014
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
J. Halstead (2005)
10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
J. van Meerbeeck (1999)



This paper is referenced by
10.1016/j.brachy.2009.08.009
High-dose-rate surface brachytherapy to boost elongated, curvilinear incisional scars after extrapleural pneumonectomy for malignant pleural mesothelioma treated with adjuvant intensity-modulated radiation therapy.
Laura A. Doyle (2010)
10.1148/rg.346130089
Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma.
Larry T Nickell (2014)
10.1016/j.clinimag.2016.05.001
Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.
Benedikt Michael Schaarschmidt (2016)
10.1111/j.1349-7006.2010.01827.x
Establishment of a cell line from a Japanese patient useful for generating an in vivo model of malignant pleural mesothelioma
A. Sato (2011)
10.1016/J.RX.2010.02.009
Solution to case 26. Malignant pleural mesothelioma
E BarcinaGarcía (2011)
10.5772/55292
Mesothelioma: An Evidence-Based Review
Julie Goudreault (2013)
Pleural mesothelioma in paraoccupational, environmental and occupational patients exposed to asbestos.
María Martha Méndez-Vargas (2010)
10.1007/s10147-011-0369-1
Pathological and molecular biological approaches to early mesothelioma
T. Tsujimura (2011)
10.1111/j.1749-6632.2010.05554.x
Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model.
Jedd M. Hillegass (2010)
10.1016/j.intimp.2020.106481
Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.
F. Zhang (2020)
10.2217/imt.12.108
Dendritic cell-based immunotherapy in mesothelioma.
R. Cornelissen (2012)
10.1007/978-1-4471-6404-3_51
Surgical and Medical Therapy for Malignant Pleural Mesothelioma
Christopher Cao (2014)
10.2217/LMT.14.17
Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice
Giovanni Luca Ceresoli (2014)
10.2482/HAIGAN.52.201
Morphological Characteristics of 9p21 Homozygous Deletion-Positive Malignant Pleural Mesothelioma Cells Detected by FISH
Kazuki Nabeshima (2012)
10.1016/j.lungcan.2011.11.014
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
Thierry M. Jahan (2012)
10.5507/bp.2014.015
Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
P. Jakubec (2015)
10.1590/1980-265x-tce-2017-0571
THERAPEUTIC ITINERARY REVEALED BY THE FAMILY MEMBERS OF INDIVIDUALS WITH MESOTHELIOMA: MULTIPLE CASE STUDIES
Fátima Denise Padilha Baran (2019)
Synergistic treatment of lung cancer with genetically modified cell therapy and chemotherapy
K. Kolluri (2016)
10.1111/cup.13026
Epithelioid malignant mesothelioma metastatic to the skin: A case report and review of the literature
R. E. Ward (2017)
10.1007/978-3-642-40582-2_7
Functional Imaging of Malignant Pleural Mesothelioma and other Pleural and Chest Wall Lesions
Jordi Broncano (2014)
10.1016/j.jtho.2017.03.015
FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma.
S. Salvi (2017)
10.1097/RMR.0000000000000162
MR Imaging of Pleural Neoplasms.
Brett W Carter (2018)
10.1016/j.lungcan.2016.01.017
Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma.
K. Martini (2016)
10.1016/J.LUNGCAN.2007.01.033
Biphasic malignant mesothelioma cases with osseous differentiation and long survival: a review of the literature.
F. Demırağ (2007)
10.1097/JTO.0b013e3181a8c874
Localized malignant pleural mesothelioma: report of two cases.
Silvia Tanzi (2009)
10.1088/0952-4746/31/1/R01
Malignant pleural mesothelioma risk among nuclear workers: a review.
Camille Metz-Flamant (2011)
10.1039/c4an01958j
A rapid and convenient method for detecting a broad spectrum of malignant cells from malignant pleuroperitoneal effusion of patients using a multifunctional NIR heptamethine dye.
Ying Tian (2015)
10.1007/978-1-84628-474-8_55
Treatment of Malignant Pleural Mesothelioma: Is There a Benefit to Pleuropneumonectomy?
S. Su (2007)
10.1007/978-0-387-72114-9_12
Neoplasms of the Pleura
S. Hammar (2008)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
Giovanni Luca Ceresoli (2011)
10.1002/jso.21787
Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research.
Dario Baratti (2011)
10.3892/MCO.2013.175
Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.
Kazuya Fukuoka (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar